2. Search Result
Search Result
Isoforms Recommended: T-type calcium channel
Results for "

CaV3.3

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Isotope-Labeled Compounds

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103309
    ML218
    2 Publications Verification

    		 Calcium Channel Neurological Disease
    ML218 is a potent, selective and orally active T-type Ca 2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .
    ML218
  • HY-W011235
    Norfluoxetine hydrochloride

    		5-HT Receptor Calcium Channel Drug Metabolite Cardiovascular Disease Neurological Disease
    Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity .
    Norfluoxetine hydrochloride
  • HY-120597
    SAK3

    		Calcium Channel Neurological Disease
    SAK3 is a potent T-type voltage-gated Ca 2+ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca 2+ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice . SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity .
    SAK3
  • HY-103309A
    ML218 hydrochloride

    		Calcium Channel Neurological Disease
    ML218 hydrochloride is a potent, selective and orally active T-type Ca 2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 hydrochloride inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 hydrochloride has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 hydrochloride can penetrate the blood-brain barrier .
    ML218 hydrochloride
  • HY-103309S
    ML218-d9

    		Calcium Channel Neurological Disease
    ML218-d9 is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .
    ML218-d9
  • HY-122201
    NSC156529

    		Calcium Channel Neurological Disease Cancer
    NSC156529 is a potent T-type calcium-channel antagonist. NSC156529 shows inhibits on Cav3.1 and Cav3.2 and o Cav3.3 without effect. NSC156529 has the potential for the research of neuropsychic and genital system diseases .
    NSC156529
  • HY-147708
    T-Type calcium channel inhibitor 2

    		Calcium Channel Cancer
    T-Type calcium channel inhibitor 2 (compound 6g) is a potent T-type calcium channel inhibitor with IC50s of 31.0, 83.1, 69.3 µM for Cav3.1 (α1G), Cav3.2 (α1H), Cav3.3 (α1I) (α1H), respectively. T-Type calcium channel inhibitor 2 shows cytotoxicity for A549, HCT-116 cells with IC50s of 5.0, 6.4 µM, respectively .
    T-Type calcium channel inhibitor 2
  • HY-RS01799
    CACNA1I Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CACNA1I Human Pre-designed siRNA Set A contains three designed siRNAs for CACNA1I gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CACNA1I Human Pre-designed siRNA Set A
    CACNA1I Human Pre-designed siRNA Set A
  • HY-103309R
    ML218 (Standard)

    		Reference Standards Calcium Channel Neurological Disease
    ML218 (Standard) is the analytical standard of ML218 (HY-103309). This product is intended for research and analytical applications. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .
    ML218 (Standard)
  • HY-156889
    Cav 3.1 blocker 1

    		Calcium Channel Neurological Disease
    Cav 3.1 blocker 1 (compound 12) is a T-type calcium channel blocker with an IC50value of 160 nM for Cav3.1. Cav 3.1 blocker 1 weakly inhibits Cav 3.2 (IC50 of 5000 nM), and shows no inhibition on Cav 3.3 and Cav 1.2 (IC50 of >10000 nM) .
    Cav 3.1 blocker 1
  • HY-W011235R
    Norfluoxetine hydrochloride (Standard)

    		Reference Standards 5-HT Receptor Calcium Channel Drug Metabolite Cardiovascular Disease Neurological Disease
    Arecoline (hydrobromide) (Standard) is the analytical standard of Arecoline (hydrobromide). This product is intended for research and analytical applications. Arecoline hydrobromide, a naturally occurring psychoactive alkaloid, is a partial agonist of nicotinic and muscarinic acetylcholine receptor. Arecoline hydrobromide exhibits stimulation, alertness, anxiolysis and anti-parasitic effects. Arecoline hydrobromide also can induce oxidative stress .
    Norfluoxetine hydrochloride (Standard)
  • HY-RS20626
    Cacna1i Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cacna1i Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cacna1i gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cacna1i Mouse Pre-designed siRNA Set A
    Cacna1i Mouse Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: